Radioligands targeting fibroblast activation protein (FAP)
Targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs) has attracted significant attention in nuclear medicine. Since these cells are present in most cancerous tissues and FAP is rarely expressed in healthy tissues, anti-FAP tracers have a potential as pan-tumor agents...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
16 November 2021
|
| In: |
Cancers
Year: 2021, Jahrgang: 13, Heft: 22, Pages: 1-12 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13225744 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers13225744 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/13/22/5744 
|
| Verfasserangaben: | Thomas Lindner, Frederik L. Giesel, Clemens Kratochwil and Sebastian E. Serfling |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1806076128 | ||
| 003 | DE-627 | ||
| 005 | 20220820195221.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220604s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13225744 |2 doi | |
| 035 | |a (DE-627)1806076128 | ||
| 035 | |a (DE-599)KXP1806076128 | ||
| 035 | |a (OCoLC)1341461148 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Lindner, Thomas |e VerfasserIn |0 (DE-588)107520318X |0 (DE-627)833005804 |0 (DE-576)443314772 |4 aut | |
| 245 | 1 | 0 | |a Radioligands targeting fibroblast activation protein (FAP) |c Thomas Lindner, Frederik L. Giesel, Clemens Kratochwil and Sebastian E. Serfling |
| 264 | 1 | |c 16 November 2021 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.06.2022 | ||
| 520 | |a Targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs) has attracted significant attention in nuclear medicine. Since these cells are present in most cancerous tissues and FAP is rarely expressed in healthy tissues, anti-FAP tracers have a potential as pan-tumor agents. Compared to the standard tumor tracer [18F]FDG, these tracers show better tumor-to-background ratios (TBR) in many indications. Unlike [18F]FDG, FAP-targeted tracers do not require exhausting preparations, such as dietary restrictions on the part of the patient, and offer the possibility of radioligand therapy (RLT) in a theragnostic approach. Although a radiolabeled antibody was clinically investigated as early as the 1990s, the breakthrough event for FAP-targeting in nuclear medicine was the introduction and clinical application of the so-called FAPI-tracers in 2018. From then, the development and application of FAP-targeted tracers became hot topics for the radiopharmaceutical and nuclear medicine community, and attracted the interest of pharmaceutical companies. The aim of this review is to provide a comprehensive overview of the development of FAP-targeted radiopharmaceuticals and their application in nuclear medicine. | ||
| 650 | 4 | |a cancer associated fibroblasts | |
| 650 | 4 | |a drug discovery | |
| 650 | 4 | |a FAP | |
| 650 | 4 | |a radiopharmaceuticals | |
| 700 | 1 | |a Giesel, Frederik L. |d 1970- |e VerfasserIn |0 (DE-588)129031240 |0 (DE-627)387883878 |0 (DE-576)297457071 |4 aut | |
| 700 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 700 | 1 | |a Serfling, Sebastian E. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 13(2021), 22, Artikel-ID 5744, Seite 1-12 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Radioligands targeting fibroblast activation protein (FAP) |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:22 |g elocationid:5744 |g pages:1-12 |g extent:12 |a Radioligands targeting fibroblast activation protein (FAP) |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13225744 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/22/5744 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220604 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 3 | ||
| 998 | |g 129031240 |a Giesel, Frederik L. |m 129031240:Giesel, Frederik L. |d 910000 |d 911400 |d 50000 |e 910000PG129031240 |e 911400PG129031240 |e 50000PG129031240 |k 0/910000/ |k 1/910000/911400/ |k 0/50000/ |p 2 | ||
| 998 | |g 107520318X |a Lindner, Thomas |m 107520318X:Lindner, Thomas |d 50000 |e 50000PL107520318X |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1806076128 |e 4143454815 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 04.06.2022"],"relHost":[{"disp":"Radioligands targeting fibroblast activation protein (FAP)Cancers","recId":"614095670","name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"part":{"issue":"22","year":"2021","pages":"1-12","volume":"13","extent":"12","text":"13(2021), 22, Artikel-ID 5744, Seite 1-12"},"origin":[{"publisherPlace":"Basel","dateIssuedDisp":"2009-","publisher":"MDPI","dateIssuedKey":"2009"}],"id":{"issn":["2072-6694"],"zdb":["2527080-1"],"eki":["614095670"]},"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.2009 -"],"language":["eng"],"note":["Gesehen am 27.05.2020"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Cancers","title_sort":"Cancers"}]}],"language":["eng"],"physDesc":[{"extent":"12 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Radioligands targeting fibroblast activation protein (FAP)","title":"Radioligands targeting fibroblast activation protein (FAP)"}],"person":[{"display":"Lindner, Thomas","given":"Thomas","role":"aut","family":"Lindner"},{"family":"Giesel","role":"aut","given":"Frederik L.","display":"Giesel, Frederik L."},{"display":"Kratochwil, Clemens","given":"Clemens","role":"aut","family":"Kratochwil"},{"display":"Serfling, Sebastian E.","family":"Serfling","role":"aut","given":"Sebastian E."}],"recId":"1806076128","name":{"displayForm":["Thomas Lindner, Frederik L. Giesel, Clemens Kratochwil and Sebastian E. Serfling"]},"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"16 November 2021"}],"id":{"doi":["10.3390/cancers13225744"],"eki":["1806076128"]}} | ||
| SRT | |a LINDNERTHORADIOLIGAN1620 | ||